Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 7/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 7/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.37 |
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.36 |
| ▸ | ITGAV | P06756 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408422 | 0.95 | ITGB1 (0.40) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| SCHEMBL7415220 | 0.93 | ITGB1 (0.36) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| SCHEMBL7417331 | 0.91 | ITGB1 (0.40) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| SCHEMBL7415119 | 0.91 | ITGB1 (0.39) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| SCHEMBL7412996 | 0.91 | ITGB3 (0.39) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| SCHEMBL7414443 | 0.90 | ITGB1 (0.39) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| Trifluoroacetic Acid SCHEMBL7415321 | 0.89 | ITGB1 (0.49) | ITGB1ITGA5ITGB3ITGA2BF2 | |
| SCHEMBL7417563 | 0.88 | ITGB3 (0.39) | ITGB3ITGA2BF2TMPRSS6ITGAV | |
| SCHEMBL7415329 | 0.88 | ITGB3 (0.35) | ITGB1ITGA5ITGB3ITGA2BITGAV | |
| SCHEMBL7415008 | 0.88 | F2 (0.42) | ITGB1ITGA5ITGB3ITGA2BF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |